CN106349338A - Pyridino-indolo-imidazole ketone butyryl-Thr-Phe-glucosamine, as well as preparation, activity and application thereof - Google Patents
Pyridino-indolo-imidazole ketone butyryl-Thr-Phe-glucosamine, as well as preparation, activity and application thereof Download PDFInfo
- Publication number
- CN106349338A CN106349338A CN201510409747.7A CN201510409747A CN106349338A CN 106349338 A CN106349338 A CN 106349338A CN 201510409747 A CN201510409747 A CN 201510409747A CN 106349338 A CN106349338 A CN 106349338A
- Authority
- CN
- China
- Prior art keywords
- tetrahydrochysene
- ketone
- base
- dimethyl
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses [(S)-2,3,4,9-tetralin-1H-pyridino-[3,4-b] indolo(2,2-dimethyl-imidazole-4-ketone-3-yl)]-2-methylbutyryl-Thr-Phe-glucosamine, and discloses a preparation method, anti-tumor action and anti-inflammatory action thereof, so that the invention discloses application of the [(S)-2,3,4,9-tetralin-1H-pyridino-[3,4-b] indolo(2,2-dimethyl-imidazole-4-ketone-3-yl)]-2-methylbutyryl-Thr-Phe-glucosamine in preparation of anti-tumor and anti-inflammatory medicines.
Description
Technical field
The present invention relates to [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2- methylbutyryl-thr-phe- Glucosamine, be related to its preparation method, it is related to its antitumor action and antiinflammatory action, thus the present invention relates to its application in preparing antineoplastic and anti-inflammatory drug.The invention belongs to biomedicine field.
Technical background
Tumour is the cell paraplasm of local organization and the neoformation that formed.All of malignant tumour is generically and collectively referred to as cancer.Malignant tumour seriously threatens human health.In the operative treatment, radiation and chemotherapy of clinical tumor, chemotherapy is most widely used, and invention good effect and the low anti-cancer agent of toxic and side effect are always the focus of drug research.In anti-cancer agent research, inventor once disclosed the compound (in formula aa be amino acid residue) of following structure, and, by 1 μm of ol/kg dosage abdominal cavity single-dose, once a day, successive administration has antitumor action in 7 days.The dissatisfied this curative effect of inventor.
Studied through 5 years, inventor finds that the aa-obzl in structure is replaced with thrt-phe- Glucosamine above, not only can strengthen antitumor activity, and can obtain extra anti-inflammatory activity.According to these results of study, inventors herein propose the present invention.
Content of the invention
First content of the present invention is to provide following formula [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2- methylbutyryl-thr-phe- Glucosamine.
Second content of the present invention is to provide [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] preparation method of -2- methylbutyryl-thr-phe- Glucosamine, the method comprises the following steps:
(1) l- tryptophan is carried out under the catalysis of sulfuric acid pictet-spengler with formaldehyde and be condensed to yield 2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acids；
(2) to 2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acids and n under ice bath, n- dimethylformamide, dmf, solution in add di-tert-butyl dicarbonate, boc2The catalysis of o, n- methyl morpholine obtains n-boc-2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acids；
(3) in dicyclohexylcarbodiimide, dcc, with n- hydroxybenzotriazole, hobt, in the presence of n-boc-2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acids are condensed as n-boc-2 in anhydrous thf (oxolane) with l-leu-ome, and 3,4,9- tetrahydro-beta-carboline -3- formyl-leu-ome；
(4) n-boc-2 in hydrogen chloride-ethyl acetate solution, 3,4,9- tetrahydro-beta-carboline -3- formyl-leu-ome slough boc and generate 2,3,4,9- tetrahydro-beta-carboline -3- formyl-leu-ome；
(5) lower 2,3,4, the 9- tetrahydro-beta-carboline -3- formyl-leu-ome of triethylamine catalysis lucifuge reaction in methyl alcohol and acetone soln obtains 2,3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl methyl esters；
(6) 2,3,4 in methanol solution, 9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl methyl esters hydrolyzes generation 2,3 in 2n naoh solution, 4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2-Methyl Butyric Acid；
(7) 2 in the presence of dcc and hobt, 3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2-Methyl Butyric Acid is condensed with thr-obzl as 2,3,4 in anhydrous dmf, 9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr-obzl；
(8) 2,3,4 under being catalyzed in pd/c, 9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr-obzl hydrogenolysis is 2,3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr；
(9) in the presence of dcc and hobt, boc-phe is condensed with Glucosamine as boc-phe- Glucosamine in anhydrous dmf；
(10) in hydrogen chloride-ethyl acetate solution, boc-phe- Glucosamine is sloughed boc and is generated phe- Glucosamine；
(11) 2 in the presence of dcc and hobt, 3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr is condensed as 2,3,4 with phe- Glucosamine in anhydrous dmf, 9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr-phe- Glucosamine.
3rd content of the present invention is evaluation 2,3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2, the effect of 2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr-phe- aminoglucose Glyco inhabiting s180 mice with tumor tumour growth.
4th content of the present invention is evaluation 2,3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2, the inhibitory action to icr mouse inflammation for the 2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr-phe- Glucosamine.
Brief description
Synthetic route .i of Fig. 1 [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2- methylbutyryl-thr-phe- Glucosamine) dilute sulfuric acid, 40% formaldehyde；ii)boc2O, dmf, triethylamine；Iii) dcc, hobt, nmm, anhydrous thf；Iv) 4n hydrogen chloride, methyl alcohol, acetone, triethylamine；v)2nnaoh；Vi) pd/c, hydrogen.
Specific embodiment
In order to the present invention is expanded on further, a series of embodiments are given below.These embodiments are entirely illustrative, and they are only used for the present invention is specifically described, and are not construed as limitation of the present invention.
Embodiment 1 prepares (s) -2,3,4,9- tetrahydro-beta-carbolines -3- carboxylic acid (1)
2500ml distilled water is placed in 2500ml reaction bulb, is slowly added to the 1.3ml concentrated sulfuric acid, stir 2min, 32.6g (159mmol) l- tryptophan is added again in the dilute sulfuric acid obtaining, ultrasonic add 65ml 40% formalin to being completely dissolved, 7h tlc (ch is stirred at room temperature2cl2∶ch3Oh, 5: 1) monitoring terminating reaction.It is slowly added dropwise concentrated ammonia liquor in reactant liquor, adjusts ph to 6, stand half an hour, filter, distilled water used respectively by filter cake, acetone washs 3 times, collect filter cake and be transferred in surface plate and dry, finally obtain 31.5g (91%) title compound, be colorless solid.esi-ms(m/e)215[m-h]-.
Embodiment 2 preparation n-boc- (s) -2,3,4,9- tetrahydro-beta-carbolines -3- carboxylic acid (2)
By 41.9g (193.9mmol) (s) -2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acids are added in 300ml dmf, add 50.8g (233mmol) (boc) under ice bath stirring in suspension2O, then dropping triethylamine tune reactant liquor ph to 10, room temperature reaction 48h, every 8h water pump is evacuated 1 time, tlc (ch2cl2∶ch3Oh, 5: 1) display raw material point disappearance, terminating reaction.Reduced pressure concentration, residue 300ml ethyl acetate dissolves, and uses 5%khso4Solution is washed 3 times, ethyl acetate layer anhydrous sodium sulfate drying 12h, filters, filtrate reduced in volume.Residue adds a small amount of ch2cl2Ultrasonic for after suspension filter, collect filter cake.Repeat the above steps after filtrate concentration, until no suspended substance terminates in solution.Collect filter cake and obtain 33.94g (55%) title compound, be colorless solid.esi-ms(m/e)315[m-h]-.
Embodiment 3 preparation n-boc- (s) -2,3,4,9- tetrahydro-beta-carbolines -3- formyl-l- leucine methyl ester (3)
By 31.35g (99.7mmol) n-boc- (s) -2 under ice bath, 3,4,9- tetrahydro-beta-carboline -3- carboxylic acid in the anhydrous thf of 250ml and adds 13.39g (99.7mmol) hobt, then plus 24.51g (119.6mmol) dcc and the anhydrous thf of 150ml solution, react 30min；Again plus 19.87g (99.7mmol) l- leucine methyl ester, reactant liquor ph to 9, room temperature reaction 24h are adjusted with nmm.Tlc (petroleum ether: acetone, 3: 1) display raw material point disappearance, terminating reaction.Filter, filtrate reduced in volume.Residue 250ml ethyl acetate dissolves, and uses saturation nahco successively3Solution is washed 3 times, and saturation nacl solution washes 3 times, 5%khso4Solution is washed 3 times, and saturation nacl solution washes 3 times, 5%nahco3Solution is washed 3 times, and saturation nacl solution washes 3 times.Ethyl acetate layer anhydrous sodium sulfate drying 12h merging, filters, filtrate reduced in volume obtains 43.42g (99%) title compound, is yellow solid.esi-ms(m/e)444[m+h]+.
Embodiment 4 prepares [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)]-methyl 2-methylbutyrate (4)
To 21.0g (48.4mmol) n-boc- (s) -2 under ice bath stirring, 3,4,9- tetrahydro-beta-carboline -3- formyl-l- leucine methyl ester instills 220ml hydrogen chloride-ethyl acetate solution (4n), under ice bath, reaction 4h tlc (petroleum ether: acetone, 3: 1) monitoring raw material point disappears.Drain solvent, residue 110ml ch3Oh dissolves, and adds 110ml acetone, adjusts reactant liquor ph to 9 with triethylamine, and room temperature lucifuge is reacted 2 weeks.Tlc (petroleum ether: acetone, 3: 1) display raw material point disappearance, terminating reaction.Reacting liquid filtering, filtrate reduced in volume has Precipitation.Refilter, filtrate reduced in volume has Precipitation again.Repeat this step, until no Precipitation.Collect filter cake.Filtrate is dissolved with 400ml ethyl acetate after concentrating, and is washed 8 times with saturation nacl solution, ethyl acetate layer filtration, filtrate reduced in volume, residue a small amount of ch after anhydrous sodium sulfate drying 12h of merging3Oh suspends, and filters, and collects filter cake.Filtrate repeats this step, until no Precipitation.Merge all filter cakes collected, dry to obtain 11.75g (65%) title compound, be colorless solid.esi-ms(m/e)384[m+h]+.
Embodiment 5 prepares [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2-Methyl Butyric Acid (5)
Add 300ml thf and 100ml ch to 10.32g (26.9mmol) [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)]-methyl 2-methylbutyrate3oh.Ice bath stirring is lower to use 2n naoh to adjust the ph to 12 of reactant liquor.Ice bath reaction 48h tlc (petroleum ether: acetone, 3: 1) monitoring raw material point disappearance, terminating reaction.Saturation khso is used under ice bath4Reactant liquor ph is adjusted to 7 by solution.Reduced pressure concentration removes thf and ch3After oh, under ice bath, use 5%khso4The ph remaining thing liquid is adjusted to 2 by solution, makes a large amount of colourless precipitate of precipitation.Filter, filter cake distills water washing with a small amount of, filter cake is dried to obtain 9.45g (95%) title compound, is light yellow solid.esi-ms(m/e)368[m-h]-.
Embodiment 6 prepares [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2- methylbutyryl-thr-obzl (6)
To 1.0g (2.74mmol) [(s) -2 under ice bath and stirring, 3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] in the solution of -2-Methyl Butyric Acid and the anhydrous thf of 90ml plus 0.37g (2.74m mol) hobt and 0.62g (3.28mmol) dcc, react 30min.Afterwards, add 1.13g (2.74mmol) l-thr-obzl and with nmm, the ph of reactant liquor is adjusted to 9, react 21h, tlc (petroleum ether: acetone, 3: 1) monitoring raw material point disappears, terminating reaction.Reacting liquid filtering, filtrate reduced in volume, residue with Ethyl acetate dissolves, and the solution obtaining uses saturation nahco successively3Solution is washed 3 times, and saturation nacl solution washes 3 times, 5%khso4Solution is washed 3 times, and saturation nacl solution washes 3 times, 5%nahco3Solution is washed 3 times, and saturation nacl solution washes 3 times.Ethyl acetate layer anhydrous sodium sulfate drying 12h, filters, filtrate reduced in volume, residue silica gel column chromatography purifies to obtain 1.3g (87%) title compound, is yellow solid.esi-ms(m/e)561[m+h]+.
Embodiment 7 prepares [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2- methylbutyryl-thr (7)
To 1.3g (2.32mmol) [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2- methylbutyryl-thr-obzl and 100ml ch3In the solution of oh plus 230mg pd/c, stir, be passed through hydrogen, react 48h, tlc (petroleum ether: acetone, 3: 1) monitoring raw material point disappears, terminating reaction.Reacting liquid filtering, filtrate reduced in volume, obtain 1.03g (94%) title compound, be yellow solid.esi-ms(m/e)469[m-h]-.
Embodiment 8 prepares boc-phe- Glucosamine
Add 5.0g (37.7mmol) hobt and 9.3g (45.2mmol) dcc in the solution of 10.0g (37.7mmol) the boc-phe and anhydrous dmf of 300ml under ice bath and stirring, react 30min.Afterwards, add 12.0g (56.6mmol) aminoglucose hydrochloride and with nmm, the ph of reactant liquor is adjusted to 9, room temperature reaction 36h, tlc (ch2cl2∶ch3oh∶ch3co2H, 15: 1: 1.5) monitoring raw material point disappearance, terminating reaction.Reacting liquid filtering, filtrate reduced in volume obtains 6.0g (38%) title compound, is colorless solid.esi-ms(m/e)425[m-h]-.
Embodiment 9 prepares phe- Glucosamine
Ice bath and lower 6.0g (14.08mmol) the boc-phe- Glucosamine of stirring react 4h, tlc (ch with 120ml 4n hydrogen chloride-ethyl acetate solution2cl2∶ch3oh∶ch3co2H, 15: 1: 1.5) monitoring raw material point disappearance, terminating reaction.Reactant liquor reduced pressure concentration, residue adds absolute ether reduced pressure concentration and removes free hydrogen chloride, obtains 5.7g (100%) title compound, is colorless solid.esl-ms(m/e)326[m+h]+.
Embodiment 10 prepares [(s) -2,3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles are simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] -2- methylbutyryl-thr-phe- Glucosamine (8)
To 100mg (0.22mmol) [(s) -2 under ice bath and stirring, 3,4,9- tetrahydrochysene -1h- pyrido [3,4-b] indoles simultaneously (2,2- dimethyl-imidazol -4- ketone -3- base)] add 30mg (0.22mmol) hobt and 95mg (0.46mmol) dcc in the solution of -2- methylbutyryl-thr and the anhydrous dmf of 20ml, react 30min.Afterwards, plus 95mg (0. 26mmol) phe acyl-Glucosamine ph of reactant liquor is adjusted to 9 with nmm, room temperature lucifuge reacts 24h.tlc(ch2cl2∶ch3oh∶ch3co2H, 15: 1: 1.5) monitoring raw material point disappearance, terminating reaction.Reacting liquid filtering, filtrate reduced in volume, residue 10ml ch3The mixed solvent dissolving of oh and 10ml distilled water, with 0.22 μm of membrane filtration of millex gp, is purified with hplc, obtains 19mg (11%) title compound, be colorless solid.esi-ms(m/e)777[m-h]-；mp 175-177℃；[α]=8.0 (c=0.1, ch3oh)；1hnmr(300mhz，dmso-d6)δ/ppm∶10.868(s，1h)，7.917(d，J=7.5hz，1h)，7.713(d，J=8.1hz，1h)，7.443(d，J=7.8hz，1h)，7.136(m，9h)，6.468(d，J=4.5hz，1h)，4.909(m，2h)，4.510(m，3h)，4.178(m，1h)，3.965(m，4h)，3.545(m，5h)，3.119(m，3h)，2.884(m，3h)，2.095(m，2h)，1.935(m，1h)，1.593(m，2h)，1.330(s，3h)，1.276(s，3h)，0.985(d，J=6.3hz，3h)，0.922(m，6h).
Experimental example 1 evaluates the activity that compound 8 suppresses s180 mice tumors grew
Before measuring, sample is dissolved by derivative physiological saline of the present invention；Adriamycin is dissolved in physiological saline.Take under aseptic condition and be inoculated in the icr mouse s180 sarcoma of 7-10 days, add appropriate normal saline tumor cells suspension, cell number is 1 × 107Individual/ml, be inoculated in health male icr mouse forelimb armpit subcutaneous, every injected in mice 0.2ml.After tumor inoculation 24h, the aqueous solution for the treatment of group mouse daily lumbar injection 0.2ml derivative of the present invention, successive administration 9 days, dosage is 0.01 μm of ol/kg.Naive mice daily lumbar injection 0.2ml physiological saline.Positive control is made with adriamycin (dosage is for 2 μm of ol/kg).Experiment was carried out to the 10th day, claimed Mouse Weight, and take the tumour of each group mouse to weigh, result lists table 1 in.As shown by data, the knurl weight of compound 8 treatment mouse is significantly less than the knurl weight of saline-treated mice.The antitumor activity that compound 8 has had is described.With the disclosed compound phase ratio mentioned in background of invention, effective dose reduces 100 times, obtains unexpected technique effect.
The impact to 8 pairs of s180 tumor-bearing mice tumour growths for table 1 compound
N=15；A) with physiological saline than p ＜ 0.01.
Experimental example 2 evaluates the anti-inflammatory activity of compound 8
20 ± 2g icr male mice is randomly divided into blank control group, positive medication group and administration group, and mouse uses front tranquillization 1 day, and operation room keeps 22 DEG C of indoor temperature, every group of mouse 10.The normal saline solution of the normal saline solution (dosage is 1.11mmol/kg) of oral normal saline (dosage is 0.2ml/20g) or aspirin or compound 8 is to after (dosage is 1 μm of ol/kg) 30 minutes, left ear gabarit toward small white mouse applies dimethylbenzene (0.045ml), by mouse anesthesia after 1 hour, cervical dislocation is put to death.The left and right ear of mouse is cut, with the card punch of diameter 7mm in the same position of two ears, takes circular auricle, weigh respectively, obtain the weight difference of two circle auricles as swelling, with Represent.This experimental data statistics is all using t inspection and variance analysis.The results are shown in Table 2.It can be seen that the mouse ear swelling degree of compound 8 treatment group has significant difference compared with physiological saline group, show that compound 8, under playing Anticancer effect in vivo, also has antiinflammatory action.With the disclosed compound phase ratio mentioned in background of invention, anti-inflammatory activity is unexpected technique effect.
The anti-inflammatory activity of table 2 compound 8
N=10；A) with physiological saline than p ＜ 0.01.
Claims (4)
1. the 2 of following formula, 3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl
- thr-phe- Glucosamine
2. the 2 of claim 1,3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methyl
The preparation method of butyryl-t-phe- Glucosamine, the method includes:
(1) l- tryptophan is carried out under the catalysis of sulfuric acid pictet-spengler with formaldehyde and be condensed to yield 2,3,4,9- tetrahydrochysene-β-click
Quinoline -3- carboxylic acid；
(2) to 2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acids and n under ice bath, n- dimethylformamide, dmf, solution in add
Di-tert-butyl dicarbonate, boc2The catalysis of o, n- methyl morpholine obtains n-boc-2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acids；
(3) in dicyclohexylcarbodiimide, dcc, and n- hydroxybenzotriazole, hobt, in the presence of n-boc-2,3,4,9- tetrahydrochysenes
- B-carboline -3- carboxylic acid is condensed as n-boc-2 in anhydrous thf (oxolane) with l-leu-ome, and 3,4,9- tetrahydrochysene-β -
Carboline -3- formyl-leu-ome；
(4) n-boc-2 in hydrogen chloride-ethyl acetate solution, 3,4,9- tetrahydro-beta-carboline -3- formyl-leu-ome slough boc life
Become 2,3,4,9- tetrahydro-beta-carboline -3- formyl-leu-ome；
(5) lower 2,3,4, the 9- tetrahydro-beta-carboline -3- formyl-leu-ome of triethylamine catalysis lucifuge reaction in methyl alcohol and acetone soln
Obtain 2,3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl methyl esters；
(6) 2,3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2 in methanol solution, 2- dimethyl-imidazol -4- ketone -3- base -2- methyl fourth
Acyl methyl esters hydrolyzes generation 2,3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2,2- dimethyl-imidazol in 2n naoh solution
- 4- ketone -3- base -2-Methyl Butyric Acid；
(7) 2,3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2 in the presence of dcc and hobt, 2- dimethyl-imidazol -4- ketone -3- base
- 2-Methyl Butyric Acid is condensed as 2 in anhydrous dmf with thr-obzl, 3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- bis-
Methyl-imidazoles -4- ketone -3- base -2- methylbutyryl-thr-obzl；
(8) 2,3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2 under being catalyzed in pd/c, 2- dimethyl-imidazol -4- ketone -3- base -2- methyl
Butyryl-thr-obzl hydrogenolysis is 2,3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- first
Base butyryl-thr；
(9) in the presence of dcc and hobt, boc-phe is condensed as boc-phe- with Glucosamine in anhydrous dmf
Glucosamine；
(10) in hydrogen chloride-ethyl acetate solution, boc-phe- Glucosamine is sloughed boc and is generated phe- Glucosamine；
(11) 2,3,4,9- tetrahydrochysene -1h- pyridine diindyl simultaneously -2 in the presence of dcc and hobt, 2- dimethyl-imidazol -4- ketone -3-
Base -2- methylbutyryl-thr is condensed as 2 in anhydrous dmf with phe- Glucosamine, 3,4,9- tetrahydrochysene -1h- pyridos
Indoles simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl-thr-phe- Glucosamine.
3. the 2 of claim 1,3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methylbutyryl
Application in the preparing antineoplastic for-thr-phe- Glucosamine.
4. the 2 of claim 1,3,4,9- tetrahydrochysene -1h- pyridine diindyls simultaneously -2,2- dimethyl-imidazol -4- ketone -3- base -2- methyl
Application in preparing anti-inflammatory drug for the butyryl-thr-phe- Glucosamine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510409747.7A CN106349338A (en) | 2015-07-13 | 2015-07-13 | Pyridino-indolo-imidazole ketone butyryl-Thr-Phe-glucosamine, as well as preparation, activity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510409747.7A CN106349338A (en) | 2015-07-13 | 2015-07-13 | Pyridino-indolo-imidazole ketone butyryl-Thr-Phe-glucosamine, as well as preparation, activity and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106349338A true CN106349338A (en) | 2017-01-25 |
Family
ID=57842115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510409747.7A Pending CN106349338A (en) | 2015-07-13 | 2015-07-13 | Pyridino-indolo-imidazole ketone butyryl-Thr-Phe-glucosamine, as well as preparation, activity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106349338A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250203A (en) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | Beta-carboline aminoacid benzyl ester, preparation method and application thereof |
-
2015
- 2015-07-13 CN CN201510409747.7A patent/CN106349338A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250203A (en) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | Beta-carboline aminoacid benzyl ester, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘俊朋: "氨基葡萄糖拟肽类衍生物的合成", 《中国优秀硕士学位论文全文数据库(电子期刊)_工程科技I辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103450329A (en) | 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters and their synthesis, anti-tumor activity and use | |
| CN109912587B (en) | Side chain protection amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof | |
| CN102241675A (en) | (1R,3S)-1-(4-hydroxyl-3-methoxycarboxyl)-1,2,3,4-tetrahydro-beta-carboline-3-formyl amino acid derivatives as well as preparation method and application thereof | |
| CN105315332A (en) | CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof | |
| CN106349340A (en) | Pyridino-indolo-imidazole ketone butyryl-Asp-glucosamine, as well as preparation, activity and application thereof | |
| CN104211759B (en) | The formamido group acid derivative of dimethoxy hydroxyphenyl β carbolines 3, it is prepared, nanostructured, activity and application | |
| CN110922415B (en) | Synthesis and application of novel anti-tumor active compound | |
| CN104826124A (en) | Chrysin and amine cyclodextrin clathrate | |
| CN106349338A (en) | Pyridino-indolo-imidazole ketone butyryl-Thr-Phe-glucosamine, as well as preparation, activity and application thereof | |
| CN107266404A (en) | A kind of neuraminidase inhibitor zanamivir derivative and preparation method thereof | |
| CN110128482A (en) | A kind of preparation method and applications of novel Pt (IV) complex with cancer target | |
| CN106349339A (en) | Pyridino-indolo-imidazole ketone butyryl-Ile-Phe-glucosamine, as well as preparation, activity and application thereof | |
| CN106349342A (en) | Pyridino-indolo-imidazole ketone butyryl-Val-Phe-glucosamine, as well as preparation, activity and application thereof | |
| CN115403561A (en) | Intracellular self-assembly protein degradation agent based on thalidomide analogue and preparation method and application thereof | |
| CN109734768B (en) | Deacetylated cedilanid glucose-based modified compound liposome and application thereof | |
| CN109988297B (en) | Preparation method of alkylated pegylated oxaliplatin precursor | |
| CN106349341A (en) | Pyridino-indolo-imidazole ketone butyryl-Asp(glucosamine)-OBzl, as well as preparation, activity and application thereof | |
| CN106279372A (en) | Double pyrido indole imidazolone-butyryl-Lys-glucosamine, it prepares, activity and application | |
| CN109912589B (en) | Glutamine amido n-hexyl carboline carboxylic acid benzyl ester, preparation, activity and application thereof | |
| CN106674180B (en) | A kind of quercetin derivative and its preparation method and application | |
| CN108822120A (en) | FL118 amino acid hydrochloride salt and the preparation method and application thereof | |
| CN106279371A (en) | Double pyrido indole imidazolone butyryl-Lys-glucosamine, it prepares, activity and application | |
| CN106317205A (en) | Pyridinoindoloimidazolonebutyryl-N<omega>-glucuronyl-Lys-OBzl, and preparation, activity and application thereof | |
| CN103435586B (en) | Containing the polyamine derivative and its preparation method and application of flavones structure | |
| CN106317204A (en) | Pyridinoindoloimidazolonebutyryl-Asp-diglucosamine, and preparation, activity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170125 |
|
| RJ01 | Rejection of invention patent application after publication |